Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1714567

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information her Department holds on the availability of Creon 25000 across the UK.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	24095
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>We are aware of ongoing intermittent supply issues with Creon 25000 gastro-resistant capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The supplier has confirmed that stock of Creon 25000 gastro resistant capsules is now available, with further deliveries scheduled in May 2024. The Department has issued guidance to healthcare professionals regarding treatment of patients, while there was disruption to the supply of Creon 25000 gastro-resistant capsules. We continue to explore all management options to manage this issue. We have asked the supplier to continue confirming their future forecasts, and to inform us of any further gaps in supply of Creon 25000 gastro-resistant capsules.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with the suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols (SSPs), and issuing NHS communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 24096 question first answered 01/05/2024 16:00:34 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4640 label Biography information for David Linden

1714568

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Shortages
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) mitigate potential future shortages of (i) Creon 25000 and (ii) other essential medicines and (b) ensure that people affected by medicine shortages have access to alternative options.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	24096
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>We are aware of ongoing intermittent supply issues with Creon 25000 gastro-resistant capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The supplier has confirmed that stock of Creon 25000 gastro resistant capsules is now available, with further deliveries scheduled in May 2024. The Department has issued guidance to healthcare professionals regarding treatment of patients, while there was disruption to the supply of Creon 25000 gastro-resistant capsules. We continue to explore all management options to manage this issue. We have asked the supplier to continue confirming their future forecasts, and to inform us of any further gaps in supply of Creon 25000 gastro-resistant capsules.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with the suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols (SSPs), and issuing NHS communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 24095 question first answered 01/05/2024 16:00:34 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4640 label Biography information for David Linden

1714690

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services and Social Services: Labour Turnover
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to improve recruitment and retention to deliver her Department's integrated one workforce approach.
tabling member constituency	Bristol South
tabling member printed	Karin Smyth
uin	24070
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>The NHS Long Term Workforce Plan sets out how we will meet the workforce needs of the future, through increasing training numbers and reforming training, working differently, and taking action to retain more staff. The plan recommends that integrated care boards (ICBs) and wider system partners prioritise actions that drive recruitment and retention of multi-disciplinary teams, in a one workforce approach.</p><p>There are a number of key national programmes aimed at supporting regions, ICBs, and providers with recruitment challenges, in growing the workforce. For example, the Overhauling Recruitment programme aims to overhaul and modernise National Health Service recruitment by encouraging innovation and wider access into NHS careers, supporting the growth of a diverse and skilled workforce to meet future demands on healthcare. NHS England will soon be engaging with ICBs and providers to support and enable this transformational change, as it prepares to publish the overhauling recruitment strategic delivery framework.</p><p>The NHS Long Term Workforce Plan also sets out how to improve culture and leadership to ensure that up to 130,000 fewer staff leave the NHS over the next 15 years. Key to this is the National Retention Programme. The programme builds on the NHS People Promise, and supports integrated care systems (ICSs), which are made up of ICBs and integrated care partnerships, regions, NHS trusts, and organisations, to improve employee experience and retain their people, and thereby reduce the NHS staff leaver rates.</p><p> </p><p>Support for organisations and ICSs can be accessed via the Retention Hub, which outlines initiatives mapped against the People Promise, access to tools, guides, and case studies to enable improvements and contact details for regional colleagues support the retention agenda in each of the seven regions. Further information is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/looking-after-our-people/the-programme-and-resources/" target="_blank">https://www.england.nhs.uk/looking-after-our-people/the-programme-and-resources/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 08:13:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4444 label Biography information for Karin Smyth

1714027

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sipavibart
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	23829
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 08:57:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope

1714079

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gabapentin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	23890
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.</p><p>The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 09:02:05 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1714094

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heart Diseases: Surgery
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the availability of heart valve surgery for (a) women and (b) ethnic minorities.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	23907
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.</p><p>In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.</p><p>To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.</p><p>In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23908 question first answered 01/05/2024 08:52:14 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4571 label Biography information for Gill Furniss

1714095

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heart Diseases: Women
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase awareness of the symptoms of heart valve disease in women.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	23908
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.</p><p>In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.</p><p>To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.</p><p>In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23907 question first answered 01/05/2024 08:52:14 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4571 label Biography information for Gill Furniss

1714139

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Professions: Labour Turnover
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with Integrated Care Boards on recruitment and retention of health workers.
tabling member constituency	Bristol South
tabling member printed	Karin Smyth
uin	23888
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The NHS Long Term Workforce Plan sets out how we will meet the workforce needs of the future, through increasing training numbers and reforming training, working differently, and taking action to retain more staff.</p><p>There are a number of key national programmes aimed at supporting regions, integrated care boards (ICBs), and providers with recruitment challenges, and growing the workforce. For example, the Overhauling Recruitment programme aims to overhaul and modernise National Health Service recruitment, encouraging innovation and wider access into NHS careers, supporting the growth of a diverse and skilled workforce to meet future demands on healthcare. NHS England will soon be engaging with ICBs and providers to support and enable this transformational change, as it prepares to publish the overhauling recruitment strategic delivery framework.</p><p>The NHS Long Term Workforce Plan also sets out how to improve culture and leadership to ensure that up to 130,000 fewer staff leave the NHS over the next 15 years. Key to this is the National Retention Programme. The programme builds on the NHS People Promise, and supports integrated care systems (ICS), which are made up of ICBs and integrated care partnerships, regions, NHS trusts, and organisations, to improve employee experience and retain their people, thereby reducing NHS staff leaver rates.</p><p> </p><p>Support for organisations and ICS can be accessed via the Retention Hub, which outlines initiatives mapped against the People Promise, access to tools, guides, and case studies, to enable improvements and contact details for regional colleagues to support the retention agenda in each of the seven regions.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 11:26:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4444 label Biography information for Karin Smyth

1714143

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England on progress on improving outcomes for patients suffering from pancreatic cancer.
tabling member constituency	Chipping Barnet
tabling member printed	Theresa Villiers
uin	23840
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Tackling cancer is a key priority for the Government. Ministers and officials continue to work closely with NHS England to increase positive outcomes for all cancer types, including pancreatic cancer. The National Health Service is delivering a range of interventions expected to increase early diagnosis and improve outcomes for those with pancreatic cancer. This includes: providing a route into pancreatic cancer surveillance for those at inherited high-risk, to identify lesions before they develop into cancer, and diagnose cancers sooner; creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types; and increasing direct access for general practitioners to arrange diagnostic tests.</p><p> </p><p>NHS England is also funding a new audit into pancreatic cancer to increase the consistency of access to treatments, and to stimulate improvements in cancer treatment and outcomes. The Royal College of Surgeons began work on this audit in October 2022, and the first report is expected in October 2024. In addition to this, the Getting it Right First Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions NHS providers need to take to improve services, as well as gathering examples of good practice to share.</p><p>The NHS is working towards its Long Term Plan ambition of diagnosing 75% of stageable cancers at stage one and two by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis. With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 09:23:30 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1500 label Biography information for Theresa Villiers

1713890

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Learning Disability: Nurses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many learning disability nurses there (a) are and (b) were in each of the last five years.
tabling member constituency	Romsey and Southampton North
tabling member printed	Caroline Nokes
uin	23730
answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>NHS England publishes monthly Hospital and Community Health Services workforce statistics for England. These include staff working for hospital trusts and core organisations, but excludes staff working for other providers such as in primary care, general practice, or social care. This data is drawn from the Electronic Staff Record, the human resources system for the National Health Service. The statistics are available at the following link:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-workforce-statistics" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-workforce-statistics</a></p><p> </p><p>A large proportion of learning disability nurses work outside NHS trusts, and we do not hold data on where they work. However, the Nursing and Midwifery Council publishes data on the number of nurses on the register across the United Kingdom, which will include nurses employed in other settings, such as education. Data is available in the Fields of Practice sheet in the permanent register data tables, at the following link:</p><p><a href="https://www.nmc.org.uk/about-us/reports-and-accounts/registration-statistics/" target="_blank">https://www.nmc.org.uk/about-us/reports-and-accounts/registration-statistics/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23731 question first answered 30/04/2024 09:48:48 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4048 label Biography information for Caroline Nokes